New Pharmaceuticals market report from GlobalData: "Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022"

Boston, MA -- (SBWire) -- 08/27/2013 --GlobalData has released its new PharmaPoint Drug Evaluation report, "Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022". Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn't considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.

View Full Report Details and Table of Contents

Albaconazole is a novel triazole antifungal that was originally developed by Palau Pharma in Barcelona, Spain, and was later licensed to Stiefel, the US based-dermatology company. Stiefel, which was acquired by GlaxoSmithKline (GSK), subsequently conducted a Phase IIb study testing multiple doses of albaconazole. Despite the successful results of the trial, albaconazole was returned to Palau Pharma when GSK decided to not pursue further development of the drug for the US market. Currently, Palau Pharma is actively in search of a development partner to test albaconazole in Phase III trials and bring it to market.

Scope

- Overview of Dermatophytic Onychomycosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Albaconazole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Albaconazole for the US from 2012 to 2022.
- Sales information covered for the US

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Dermatophytic Onychomycosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Albaconazole performance
- Obtain sales forecast for Albaconazole from 2012 to 2022 in the US

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
- TDT-067 (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Luliconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Efinaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Itraconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Griseofulvin (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Fluconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
- Ketoconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022